Answers are grounded in this paper and cite their sources.
Cystic fibrosis (CF) is a multisystem disease transmitted through an autosomal recessive (AR) inheritance pattern, occurring due to mutations in the CF transmembrane conductance regulator (CFTR) gene which is located on chromosome 7. This mutation disrupts the normal transport of chloride ions across epithelial membranes, leading to a range of multisystem abnormalities. CF is less frequently reported in the Asian population, largely due to underdiagnosis and lack of centralized CF patient registries.[1] The burden of CF in India is anticipated to be significant due to its large population size, even though the CF incidence is estimated to be 1 in 40,000 live births.[2] The median age at diagnosis is reported as 22 months,[3] highlighting significant delays in both the presentation of symptoms and the diagnosis itself. These delays are primarily due to rarity of the condition, absence of neonatal screening for the disease as well as limited awareness among pediatricians about the entity. Consequently, CF children often present with Pseudomonas colonization, significant malnutrition and concerning signs of advanced pulmonary disease.[4] The diagnostic criteria for CF used in the western world typically involve detection of elevated sweat chloride levels, confirmation of two pathogenic CFTR mutations, and nasal potential difference which is abnormal.[5] It is difficult to do these tests in low and middle income countries. Accessibility to sweat chloride testing, which is considered as the gold standard for diagnosing CF, is limited in most developing countries. The patients might need to travel long distances, possibly hundreds of kilometers, to undergo the sweat test. The creation of an affordable, indigenous method for sweat testing, utilizing the sweat collection technique developed by Gibson and Cook, along with manual titration for chloride estimation was a breakthrough. The cost of required essential equipment is approximately US$ 10, while the cost per test is around US$ 0.30.[6] Molecular testing for confirmation of CF involves finding of two pathogenic mutations in the CFTR gene. The delta F508 mutation, which accounts for over two-thirds of cases in western populations, is found in only 15%–20% of Indian patients. Given the diverse and heterogeneous nature of the mutation profile, mutations of uncertain significance are commonly detected.[1] In children exhibiting common clinical symptoms such as respiratory, gastrointestinal, or genitourinary, additional typical signs—such as rectal prolapse, steatorrhea, failure to thrive, dyselectrolytemia, metabolic alkalosis etc. may serve as a markers suggesting a diagnosis of CF.[4,6] Additionally, history of meconium ileus, consanguinity, sibling deaths (especially with respiratory involvement), recurrent respiratory infections, features of intestinal obstruction, salty kiss, salt frosting, findings of diffuse lung disease, hyperinflation and on investigation hyponatremic hypochloremic metabolic alkalosis may also act as soft pointers indicating CF. Chest radiography reflecting classic findings of chronic bronchiectasis i.e. hyperinflation, mucoid impaction, peribronchial cuffing, bronchial thickening and dilatation, scattered nodular densities, cystic radiolucencies and an increase in interstitial markings may also complement towards CF diagnosis. Pediatric patients located in hot and humid regions are more prone to excess sweating, which may lead to the abnormal laboratory findings of hyponatremia, hypochloremia, and metabolic alkalosis.[3] Reports from tropical countries indicate that CF infants and young children often present as pseudo-Bartter syndrome typically characterized by dyselectrolytemia and metabolic alkalosis.[7] The cautions to be observed while interpreting the electrolyte imbalances and metabolic disturbances as clues to CF are that they are typically temporary and may not be present during the evaluation. Certain episodes of electrolyte imbalances and dehydration may have been empirically managed with rehydration fluids, potentially correcting the metabolic disturbance without directly measuring serum electrolyte levels or assessing blood acid-base status. Evaluation of fat malabsorption in suspected CF children with pancreatic insufficiency is ascertained by testing stools for fat globules or by estimation of feacal elastase. However, certain CF mutations furnish the CF patients as pancreatic sufficient, therefore there is a likelihood of missing the diagnosis if fully relied upon, rendering these as good ‘rule in’ tests for the diagnosis of CF. A similar pattern is associated with sweat chloride test, where specific known CF mutations do not cause elevated sweat chloride and an intermediate sweat range may reflect a heterozygous carrier state.[8] Aquagenic wrinkling, which refers to the wrinkling of hands after submerging them in water for 3 minutes, has been shown to have a sensitivity of 81% and a specificity of 57% in comparison to sweat chloride testing for diagnosing CF.[9] Multiple studies from developing countries documented the microbiological profiles of children with CF and showed frequent colonization with Pseudomonas even in infants. A sputum culture showing growth of one of the ‘signature organisms’ in the airways of CF children, including Pseudomonas aeruginosa (a pathogen commonly observed at diagnosis in CF children, particularly in developing countries), Staphylococcus aureus (both methicillin sensitive and resistant), Burkholderia cepacia, Stenotrophomonas maltophilia, Achromobacter xylosoxidans, Mycobacterium Tuberculosis, Aspergillus etc. may also be helpful as an important surrogate marker to indicate a diagnosis of CF.[10] These parameters have also been investigated in combination for diagnosing CF, with studies showing that scores—derived from clinical manifestations, aquagenic wrinkling, and fundamental laboratory investigations— demonstrate a comparable degree of accuracy to the sweat chloride test. While the sensitivity and specificity of these scores are notably lower than the conventional gold standard test, it provides a valuable initial alternative in situations where performing a sweat chloride test is not practical. This algorithm cannot be relied upon to definitively diagnose or exclude CF but it could help with the early diagnosis of presumptive CF, enabling the initiation of treatment sooner, which may contribute to preserving lung function in these children.[3] All children in this category would need referral to specialized centers for confirmatory diagnostic testing. Although the delta F508 and 3849 + 10 kb C>T splice mutations are less common in the Indian population, yet they are the most prevalent in the developing countries, therefore initial testing for these 2 hotspot mutations with affordable molecular techniques like amplification refractory mutation system polymerase chain reaction (ARMS-PCR) and restriction fragment length polymorphism (RFLP) followed by Sanger sequencing, before going for expensive next-generation sequencing (NGS), are feasible cost-effective screening options for CF genetic testing in the developing countries (unpublished data of an ICMR project from the author’s institute). The identification of two CFTR mutations through NGS could offer a feasible substitute for sweat chloride tests in remote regions. Blood samples can be transported more easily to centralized laboratories, making this approach useful, especially for critically ill children. Genetic testing is hindered by high costs and the difficulty of interpreting variants of unknown significance, especially in populations in which delta F508 mutation is rare. There is also an urgent need to explore the role of genetics in advancing our understanding of CF in the developing world as well, especially in relation to how genetic insights are shaping both current and emerging therapies. As treatment has evolved from simply alleviating symptoms to targeting specific molecular defects, genetics has become crucial in identifying the most effective precision therapies for each individual with CF. Offering these novel therapeutic approaches to a greater number of individuals as well as working towards a cure requires genetics to be looked at as not just a diagnostic tool but also as a therapeutic revolution even in the developing world.[11] CF being an AR disease, antenatal counseling about the inheritance pattern and prenatal testing for the CF mutations identified in families with children affected with CF, would go a long way in preventing birth of CF affected children and also in reducing burden of CF health related cost in the developing countries. The Union Ministry of Health & Family Welfare, Government of India has also come up with the National Policy for Rare Diseases (NPRD) sine 2021 which provides financial support under the Umbrella Scheme of Rashtriya Arogya Nidhi (RAN) for patients suffering from any category of the Rare Diseases at 12 Centers of Excellence (CoE) across the country, which includes CF and the author’s institute is one of the CoE. There is a need to think beyond the realm and expand the offered benefits to CF diagnostics as well, which are still not included in this program, especially in an era when provision of novel CFTR modulator therapies hinges on genetic diagnosis of the CF patients. A comprehensive diagnostic approach that combines key clinical features (notably sputum analysis, metabolic alkalosis, stool fat globules/fecal elastase, electrolyte testing and aquagenic wrinkling) offers a reliable means of diagnosis in resource-limited settings where sweat chloride testing may not be accessible. High index of suspicion amongst clinicians, especially among pediatricians is the key to CF diagnosis. Needless to emphasize, this can help to diagnose suspected CF children early to initiate targeted treatment while awaiting confirmation. Further, children suspected to have CF should be referred to specialized centers for sweat chloride and genetic testing, on priority. Facilities for genetic testing should be offered at subsidized costs by the governments in proportion to the requirements of the masses. We suggest undertaking extensive molecular research to annotate CFTR variants region wise, which will allow individuals with CF in developing countries also, to benefit from the advancements in precision medicine that are currently gaining momentum in the west. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest.
No takes yet. Share an insight, caveat, or question.
Vaidya et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: